Zheng Wu
邬征
Zheng Wu (邬征) is the founder of Ark Biosciences (爱科百发), where he serves as chairman and CEO . The company develops antiviral drugs — its lead asset is ziresovir, described as the first RSV-specific antiviral, whose research results were published in The Lancet Child & Adolescent Health; Wu presented the work himself in a keynote at the 13th global RSV symposium in Brazil in March 2025, per Qiming Venture Partners' portfolio coverage . Ark Biosciences is a Qiming portfolio company, and Wu appeared at Qiming's 17th RMB fund annual meeting in June 2026 on a panel about Chinese innovative drugs going global . Elsewhere's corpus doesn't carry a deeper biography of him beyond these Qiming-sourced appearances.
AI-generated — may contain errors, please verify.
Coverage
Qiming Headlines: Intelligence Ignites the Future — Qiming Venture Partners' 17th RMB Fund Annual Meeting and Investor Summit Successfully Held in Shanghai
Qiming Venture Partners Maintains Investment Discipline, Proactively Captures Market Opportunities as Deal Flow Continues
Qiming Weekly | Top 10 News from Qiming Venture Partners Portfolio Companies Vol.07, 2026.3.4
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Qiming Star | Ark Biosciences Announces Latest Research Results for First RSV-Specific Antiviral Drug Ziresovir Published in The Lancet Child & Adolescent Health | Bilingual
This study, the world's first Phase 3 clinical trial covering RSV-infected infants under six months of age, successfully fills the evidence gap for targeted treatment approaches in this high-risk population and provides critical evidence for building a comprehensive RSV disease management system.
